LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Integrated LC-MS System to Be Released in Conjunction with AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: The CLAM-2000 automated LC-MS sample preparation system (Photo courtesy of Shimadzu Scientific Instruments).
Image: The CLAM-2000 automated LC-MS sample preparation system (Photo courtesy of Shimadzu Scientific Instruments).
What may be the first truly integrated sample preparation system for LC-MS (liquid chromatography-mass spectrometry) that allows users to process samples in an instrument that is directly attached to the LC-MS system is to be released at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Shimadzu Scientific Instruments (Kyoto, Japan) had announced that the release of the Clinical Laboratory Automation Module-2000 (CLAM-2000), a fully integrated sample pretreatment module for LC-MS, will coincide with the 2016 AACC Annual Meeting.

The CLAM-2000 system, which is on display in Booth 4054 of the expo, automatically performs all the processes necessary for analyzing blood and other biological samples, from scanning in information from the blood collection tubes to sample pretreatment and LC-MS analysis. The for-research-use-only instrument is the first truly integrated sample preparation system for LC-MS. It allows users to process samples in an instrument that is directly attached to the LC-MS system, a simple and safe way for lab personnel to process and analyze samples.

The instrument is controlled by a user-friendly interface that offers a variety of functions that regulate reagent management, calibration curve management, control management, and system maintenance management. By automating operations such as dispensing, stirring, filtering, heating, and sample transfer, the system effectively improves data accuracy and achieves the high level of reproducibility needed for clinical research.

“This system highlights the considerable progress made in the use of mass spectrometers for high-sensitivity detection in medical R&D,” said Dr. Scott Kuzdzal, general manager of marketing at Shimadzu Scientific Instruments. “It is ideal for medical research centers, university medical departments, hospital pharmaceutical departments, and contract research organizations that are dealing with issues of variability in analytical results or laboratory efficiency. It can also effectively support forensic applications conducted by universities, research institutes, and testing companies.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Shimadzu Scientific Instruments
Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.